A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 08 Jul 2017
At a glance
- Drugs Irinotecan (Primary) ; Irinotecan (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Athenex
- 17 May 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jun 2017.
- 16 Nov 2016 Planned number of patients changed from 36 to 70.
- 16 Nov 2016 Planned End Date changed from 1 Sep 2016 to 1 Sep 2017.